These results suggest that the simultaneous targeting of CypA/CD147 and EGFR can more effectively suppress EGFR-mutant NSCLC CSC growth by disrupting crosstalk between the CypA/CD147 and EGFR pathways. The gene discussed is PPIA; the disease is non-small cell lung carcinoma.